What is Citigroup's price target for CANO?

Citigroup's latest stated price target for Cano Health Inc. (CANO) is $0.80, from its action on Aug 11, 2023.

What is Citigroup's rating on CANO?

Citigroup rates CANO Neutral, a neutral rating, as of Aug 11, 2023.

When did Citigroup last change its view on CANO?

On Aug 11, 2023, Citigroup downgrades to Neutral from Buy, price target $4 to $0.80.

Citigroup CANO price target and rating history

Citigroup rates Cano Health Inc. (CANO) Neutral with a $0.80 price target, as of its latest action on Aug 11, 2023. It has published 3 rating actions on CANO since September 2021, including 0 upgrades and 1 downgrade.

Current rating: Neutral
Price target: $0.80
Median target, all firms: Too few
Actions on CANO: 3

Citigroup price target on CANO

Citigroup price target on CANO, each point a stated target, September 2021 to August 2023. Targets before August 2023 (divided by 3) are adjusted for a stock split, going by the prior target Citigroup restated.

Every Citigroup rating on CANO

Aug 11, 2023
DowngradeCitigroup downgrades to Neutral from Buy, price target $4 to $0.80
Jan 10, 2022
ResumeCitigroup resumes coverage at Buy, price target $20 to $12
Sep 21, 2021
InitiateCitigroup starts coverage at Buy, price target $20

Questions about Citigroup and CANO

What is Citigroup's price target for CANO?: Citigroup's latest stated price target for Cano Health Inc. (CANO) is $0.80, from its action on Aug 11, 2023.
What is Citigroup's rating on CANO?: Citigroup rates CANO Neutral, a neutral rating, as of Aug 11, 2023.
When did Citigroup last change its view on CANO?: On Aug 11, 2023, Citigroup downgrades to Neutral from Buy, price target $4 to $0.80.

More CANO rating histories

All Citigroup ratings CANO news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.